Edition:
United States

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
18 Jun 2018
Change (% chg)

$0.02 (+5.77%)
Prev Close
$0.29
Open
$0.29
Day's High
$0.31
Day's Low
$0.26
Volume
122,891
Avg. Vol
399,062
52-wk High
$2.96
52-wk Low
$0.21

Summary

Name Age Since Current Position

Paul Truex

48 2016 Executive Chairman of the Board

Craig Thompson

50 2016 President, Chief Executive Officer, Chief Operating Officer, Director

May Liu

41 2013 Senior Vice President - Finance and Administration, Principal Accounting Officer

Brent Furse

48 2016 Independent Director

Christopher Henney

77 2016 Independent Director

Brian Mueller

43 2014 Independent Director

Philip Sager

61 2014 Independent Director

David Thompson

69 2005 Independent Director

Biographies

Name Description

Paul Truex

Mr. Paul F. Truex serves as Executive Chairman of the Board of the Company. He was President, Chief Executive Officer of Anthera Pharmaceuticals Inc. He was responsible for negotiating our product licenses for both blisibimod, our anti-BAFF peptibody program from Amgen, Inc. and Sollpura™ (liprotamase), a novel enzyme product, from Eli Lilly and Company. Mr. Truex was also responsible for our development and commercial partnership for blisibimod with Zenyaku Kogyo, Ltd. in Japan. Prior to founding Anthera, Mr. Truex served as a founder, Director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc. (“Peninsula”), from the commencement of its operations in October 2001. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson for $245 million in an all cash transaction. The remaining entity, Cerexa was subsequently acquired for $480 million in cash by Forest Laboratories. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor, Inc. (acquired by Pfizer) from April 2000 to September 2001 where he directed early commercial efforts for Versicor’s infectious disease portfolio and participated in Versicor’s initial public offering. From July 1997 to April 2000, Mr. Truex worked at Eli Lilly and Company (“Eli Lilly”) where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®' Evista®' and Humalog 75/25®). His business development experience included the Lilly ICOS LLC joint venture's two major product divestitures and numerous small research collaborations. Mr. Truex obtained his M.B.A. in marketing and finance from Indiana University and a B.A. in economics from the University of Waterloo.

Craig Thompson

Mr. Craig Thompson serves as President, Chief Executive Officer, Chief Operating Officer, Director of Anthera Pharmaceuticals, Inc. He was appointed to serve as the Company’s President effective January 7, 2016 and to serve on the board of directors and as the Company’s Chief Executive Officer effective December 6, 2016. Mr. Thompson has over 20 years of experience in pharmaceutical development and commercialization. Most recently he served as the Chief Operating Officer for Tetraphase Pharmaceuticals from February 2014 to December 2015, where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, from January 2011 to December 2014, Mr. Thompson served as the Chief Commercial Officer for Trius Therapeutics resulting in the acquisition of Trius by Cubist Pharmaceuticals for over $700 million. Prior to Trius Therapeutics, Mr. Thompson held various positions of increasing responsibility with Pfizer from November 2003 to December 2010, with his last position as Vice President of Marketing, Specialty Care. Prior to Pfizer he held various positions of increasing responsibility at Merck and Co, Inc. from April 1993 to November 2003. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and a Master’s degree in Business Administration from the University of Notre Dame.

May Liu

Ms. May Liu has is Senior Vice President - Finance and Administration, Principal Accounting Officer of Anthera Pharmaceuticals, Inc., effective June 12, 2013. Prior to that, she served as our Vice President, Finance from January 2011 to June 2013, and as our Corporate Controller from October 2007 to January 2011. Ms. Liu joined us as our Director of Finance in April 2007. Prior to joining us, Ms. Liu served as SEC Reporting and Technical Accounting Manager at Renovis, Inc., a clinical-stage pharmaceutical company, from October 2005 to March 2007. Ms. Liu has been a Certified Public Accountant since 2007 and was a part of Ernst & Young LLP’s audit and assurance practice from 2000 to 2005, focusing primarily in the life science industry. Ms. Liu holds a B.S. in business administration with a concentration in accounting from San Francisco State University.

Brent Furse

Mr. Brent Furse is Independent Director of the Company. Mr. Furse has over 25 years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing, commercial product launch and partnerships. Mr. Furse currently serves as President and Chief Commercial Officer at Cardiorentis AG, a biopharmaceutical company that is developing novel medicines for acute heart failure. Prior to Cardiorentis AG, from 2000 to 2015, Mr. Furse served as Chief Customer Officer and Executive Vice President at The Medicines Company (Nasdaq: MDCO). Prior to the Medicines Company, he worked in the cardiovascular divisions of Schering-Plough and Bristol-Myers Squibb. Mr. Furse holds a Bachelor of Science from Keenesaw State University and holds an M.B.A. from Mercer University.

Christopher Henney

Dr. Christopher S. Henney, Ph.D., serves as Independent Director of the Company. Dr. Henney served as the Chairman of our Board of Directors from August 2008 until December 2016 and has been a member of our Board of Directors since April 2005. Dr. Henney has served as Chairman and Chief Executive Officer of Dendreon Corporation, a biotechnology company he co-founded, from 1995 until his retirement in July 2004. Dr. Henney founded Immunex Corp. and ICOS Corp. and served as an executive officer and director in both companies. Dr. Henney is currently the Chairman and a director of Cascadian Therapeutics (formerly Oncothyreon, Inc.) (Nasdaq: CASC) and has served as its interim President and Chief Executive Officer from January 11, 2016 until April 2016. Dr. Henney is also a Vice-Chairman and a director of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), and a director of Prothena Corporation (Nasdaq: PRTA). Dr. Henney served as a director of AVI BioPharma Inc. from March 2009 until June 2010, and as a director of Mymetics Corporation from March 2012 until November 2012. Dr. Henney holds a B.Sc. with honors in medical biochemistry, a Ph.D. in experimental pathology and a D.Sc. for contributions to the field of immunology, all from the University of Birmingham, England. In 2012, Dr. Henney was elected to the International Biotechnology CEOs Hall of Fame.

Brian Mueller

Mr. Brian R. Mueller is Independent Director of Anthera Pharmaceuticals Inc. He currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN). From March 2009 to March 2014, Mr. Mueller served as BioMarin’s Vice President, Corporate Controller. Prior to joining BioMarin in 2002, Mr. Mueller spent a combination of seven years in public accounting with Arthur Andersen, LLP and KPMG, LLP in the audit and business advisory services practices of both firms. Mr. Mueller holds a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.

Philip Sager

Dr. Philip T. Sager, M.D., is Independent Director of Anthera Pharmaceuticals Inc. He is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society. Dr. Sager has been a member of the International Conference on Harmonization (“ICH”) E14 Discussion Group since 2014, a full voting member of the United States Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee from 2011 until July 2016 and has been the Chair of such Committee since 2016. Dr. Sager has also been a member of the Executive Committee of the Cardiac Safety Research Consortium since 2016, and served as Chair of the Scientific Programs Committee and Scientific Oversight Committee at various times. Dr. Sager has served as a Consulting or Adjunct Professor of Medicine at the Stanford University School of Medicine since 2013 and provided pharmaceutical device and diagnostics consulting service independently since 2010. From 2009 through 2010, Dr. Sager was Vice President, Clinical Research and Head, CV/Metabolic Development for Gilead Sciences, a biotechnology company. Dr. Sager holds an M.D. from Yale University School of Medicine and B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology.

David Thompson

Mr. David E. Thompson is Independent Director of Anthera Pharmaceuticals, Inc. He served as Vice President of Corporate Strategy Business Development for Eli Lilly and Company from January 2001 until his retirement in July 2005. Thereafter, he was a partner at VantagePoint Venture Partners from 2006 through 2008. Mr. Thompson holds a B.S. and an M.B.A. from Michigan State University.

Basic Compensation

Name Fiscal Year Total

Paul Truex

1,448,210

Craig Thompson

2,319,850

May Liu

592,612

Brent Furse

--

Christopher Henney

--

Brian Mueller

--

Philip Sager

--

David Thompson

--
As Of  30 Dec 2016

Options Compensation